Search

Highlights of the SWG

SWG business meetingWe held a key strategic SWG business meeting on November 29, 2023, at the EHA offices in The Hague. During the meeting, we discussed the future plans and priorities of our SWG.

Read more

Press Release: “Building the knowledge economy in the world of blood diseases: patients, professionals and Parliamentarians help make the new Europe.”

Brussels, 29th August 2011

On the 30th & 31st of August a conference will be hosted in the European Parliament that will demonstrate the leading role haematology will have in securing the future knowledge economy envisaged in the Europe 2020 Strategy.…

Read more

European Reference Networks, a unique opportunity to take collaboration and patient care in hematology to the next level, was a core topic at EHA 2016

On Saturday 11 June, a session in the Patient Advocacy Track focused on the emerging European Reference Networks (ERNs).

Read more

Starting this November: EHA Guidelines Workshops!

EHA has initiated a series of online workshops dedicated to guidelines (produced or endorsed by EHA) for diagnosis and treatment of hematologic diseases.

Read more

International CML adherence survey launched

The drivers behind non-adherence, a highly prevalent problem in oral cancer treatments but also in many other diseases like diabetes, are not well understood to date.

Read more

Meet Irene Roberts, our September volunteer of the month

Can you tell us what you do for EHA and when you started?
I joined EHA in 2003 and shortly afterwards I was lucky enough to be elected as a member of the EHA Board.

Read more

Meet Irene Roberts, our September volunteer of the month

Can you tell us what you do for EHA and when you started?
I joined EHA in 2003 and shortly afterwards I was lucky enough to be elected as a member of the EHA Board.

Read more

Young researchers to benefit from EHA training and mentoring

Participation in EHA-CRTH will allow these researchers to fine-tune the skills and knowledge required to successfully design, run and complete clinical trials.

Read more